(Wednesday, 7/15/2020) 2:00 PM - 3:00 PM [Eastern Time (GMT-4)]
Room: Track 5
According to NCI estimates, within ten years, half of all radiation therapy will include Radiopharmaceutical Therapy (RPT), also known as Theranostics, Targeted Radiotherapy or Therapeutic Nuclear Medicine. As an indication of this direction, there has recently been a huge resurgence of interest in this modality. Clinicians from both Nuclear Medicine and Radiation Oncology are learning how to introduce or build RPT programs en masse. This symposium aims to prepare the physicist for this eventuality and arm them with the tools needed to support and help grow the new RPT programs. This symposium also aims to educate physicists in the basics of radiopharmaceutical therapy in general, what distinguishes it from external beam therapy and from diagnostic nuclear medicine. Competency for several levels of will be addressed, with a large focus being on the fixed or mass-based activity or “no dosimetry” paradigm that is the entry level application and currently the only FDA-approved dosing. Subjects broached for setting up a RPT program will include applying for licenses, dose calibrator settings, activity standards, and radiation safety aspects that vary as a function of modality. Finally, the physicist will be given guidance on how to look beyond the basics and how to introduce dosimetry into the RPT program with an introduction to the different methodologies (absorbed fraction vs. Monte Carlo) and uses for dosimetry (retrospective vs. prospective, tumor vs. normal tissue).
Learning Objectives:
1. Set up and Oversee a Radiopharmaceutical Program
2. Identify the different safety concerns for the different radiopharmaceuticals
3. Identify and use Monte Carlo-based RNT dosimetry commercial software retrospectively.
Funding Support, Disclosures, and Conflict of Interest: PI licensed to Radiopharmaceutical Imaging and Dosimetry, LLC (RAPID)
Handouts
Keywords
Not Applicable / None Entered.
Taxonomy
Not Applicable / None Entered.
Contact Email
